Clinical Trial: Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer

U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07756593) titled 'Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer' on Aug. 06.

Brief Summary: This phase Ib single-center open-label de-escalation study uses a modified 3+3 design to determine the safety, tolerability, and recommended phase II dose (RP2D) of the combination of standard of care Sip-T and N-803 in patients with metastatic androgen pathway modulation resistant (mAPMR) prostate cancer. Patients will receive treatment for up to 8 weeks.

Study Start Date: Nov. 30, 2026

Study Type: INTERVENTIONAL

Condition: Prostate Cancer Metastatic Prostate Cancer

Intervention...